

# Placebo- Controlled Trial of Pharmaceutical Optimized Captopril 60mg (F-9) in Patients with Essential Hypertension for Efficacy & Biochemical Evaluation

Asnad<sup>1</sup>, Mohammad Sadiq<sup>2</sup>, Iftikhar Ahmad Chaudary<sup>4</sup> and Asma Qayume<sup>3</sup>

## ABSTRACT

**Objective:** The aim of study, to evaluate the efficacy of optimized Captopril 60 mg (F-9) with compare to placebo control for eight weeks and also analyze basic metabolism parameter such as Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides and Fasting blood glucose for test and control patients

**Study Design:** Double-blind, randomized placebo-controlled trial

**Place and Duration of Study:** This study was conducted at the Department of Biochemistry, University of Karachi from September 2011 to January 2012.

**Materials and Methods:** Patients were selected from different area of orange town and surrounding area, such as pirabad, mangopir, Pathan colony, impear colony, mastanchali, Metrovell and site area. Total eighty (80) patients were analyzed for Total Cholesterol (mg/dl), HDL-Cholesterol (mg/dl), LDL-Cholesterol (mg/dl), Triglycerides (mg/dl) and for fasting glucose level. The analysis was performed by Micro Labe 300 and kits were used of Merck. Other biochemical parameters (Liver function test, Urea, Complete blood counting, uric acid, electrolytes and protein profile) were used for safety purpose. All the parameter were studied at initial phase for test and control and after completion of trial such as eight weeks (8 weeks), parameters were studied again for test and control. Primary blood pressure such as Systolic BP - 24 hours (mmHg) and Diastolic BP - 24 hours (mmHg) was analyzed by manual method patients. After eight weeks (8 weeks) trial, blood pressure was determined by same manual method for test and placebo control patients.

**Results:** Initial result systolic blood for test patient was  $149.9 \pm 11.2$  mmHg and for placebo control was  $149.2 \pm 10.5$  mmHg. After eight week trial of optimized Captopril 60mg (F-9), systolic blood was reduced ( $140.1 \pm 11.4$  mmHg) as compared to placebo control such as ( $148.9 \pm 11.3$  mmHg). Like systolic blood pressure, initial diastolic blood pressure for test patient was ( $97.7 \pm 7.2$  mmHg) and for placebo was ( $95.3 \pm 7.7$  mmHg) but after eight week trial of optimized Captopril 60mg (F-9), diastolic blood pressure was reduced in test patients ( $86.6 \pm 5.4$  mmHg) as compared to placebo control such as ( $93.9 \pm 7.9$  mmHg).

**Conclusion:** The optimized Captopril 60mg (F-9) it is an excellent option for the treatment of hypertension with high antihypertensive efficacy, good tolerability and no biochemical effects. It is due to low dose drug and also no effect of excipient of formulation of F-9.

**Key Words:** Hypertension, Captopril, Biochemical effects

**Citation of article:** Asnad, Sadiq M, Chaudary IA, Qayume A. Placebo- Controlled Trial of Pharmaceutical Optimized Captopril 60mg (F-9) in Patients with Essential Hypertension for Efficacy & Biochemical Evaluation. Med Forum 2016;27(12):60-64.

## INTRODUCTION

The treatment of hypertension is an accurate blood pressure and high blood pressure is the risk of morbidity and mortality cardiovascular so it is essential to treat it

properly. The additional benefits regarding both protection of organs and cardiovascular mortality to control blood pressure lower than 130/85 mmHg according Guidelines of World Health Organization for the treatment of hypertension while the previous limit was 140/90 mmHg.<sup>1-6</sup>

Blood pressure is also associated with the progression of renal disease.<sup>7</sup> for the limiting renal-disease progression antihypertensive agents; inhibitors of angiotensin-converting enzyme (ACE) are regarded as particularly effective. The patients with macro-albuminuria in renal diseases ACE inhibitors significantly effective.<sup>7</sup> The beneficial effect also found in microalbuminuria patients.<sup>8,9</sup> It is reasonable to investigate whether use of ACE inhibitors in patients with normoalbuminuria may also be beneficial. ACE

<sup>1</sup>. Department of Biochemistry / Pathology<sup>2</sup> / Community Medicine<sup>3</sup>, MBBS Medical College, Mirpur AJ&K.

<sup>4</sup>. Department of Community Medicine, Poonch Medical College Rawalakot, AJ&K.

Correspondence: Dr. Asnad, Assistant Professor of Biochemistry, MBBS Medical College, Mirpur AJ&K.

Contact No: 0332-3698204

Email: drasnadkhan@gmail.com

Received: September 03, 2016; Accepted: October 30, 2016

inhibitors can slow the relentless decline of renal function in patients. However, previous trials of ACE inhibitors in normoalbuminuric patients are few,<sup>10</sup> and have either lacked power or have not been designed as randomized and controlled.<sup>10, 11</sup> For congestive heart failure and treatment of hypertension, Captopril, (1-[(2S)-3-mercapto-2-methyl propionyl]-L-proline), an angiotensin-converting enzyme inhibitor is used.<sup>12</sup>

This drug is water soluble and 1.7 h is elimination half-life after an oral dose.<sup>13</sup> pH 1.2 is stable pH and degradation reaction of drug occurred with increasing pH.<sup>14</sup> The controlled release dosage form of the drug is beneficial.<sup>15,16</sup> The hydrodynamically balanced system in which to develop floating systems to control drug release. Various attempts have been made.<sup>17, 18</sup> For the managing children with heart failure, Captopril is established pharmacological treatment. With acquired heart disease in adult drug efficacy and safety is founded data from studies, these drugs used.<sup>19, 20</sup> Clinicians used without any doubt regarding efficacy and utility of captopril for the treatment of children with heart failure, also regarding toxicity and optimal dosing schedules.<sup>19,20</sup> Formulation of the dosage form is also an important factor regarding toxicity and optimal dosing schedules.<sup>21</sup> Studies showed that angiotensin receptor blockers like olmesartan medoxomil have an antihypertensive efficacy and superior tolerability.<sup>22</sup> Another study showed that for the effectiveness and tolerance in patient with hypertension, olmesartan, medoxomil and amlodipine besylate is used.<sup>23</sup> Amlodipine besylate alone as indicated with benazepril hydrochloride with valsartan and with perindopril showed best result in reduction of blood pressure in combination form.<sup>24, 25</sup>

The aim of study, to evaluate the efficacy of optimized Captopril 60 mg (F-9) with compare to placebo control for eight weeks and also analyze basic metabolism parameter such as Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides and Fasting blood glucose for test and control patients.

## MATERIALS AND METHODS

In this study, Patient was received randomized Captopril 60mg (F-9) for eight weeks and control received placebo for eight weeks so it was multicenter, comparative study. In September 2011 to January 2012, this study was completed in the department of biochemistry, University of Karachi. Patients were selected from different area of orange town and surrounding area, such as Pirabad, Mangopir, Pathan colony, Impear colony, Mastanchali, Metrovell and site area. Total eighty (80) patients were analyzed for Total Cholesterol (mg/dl), HDL-Cholesterol (mg/dl), LDL-Cholesterol (mg/dl), Triglycerides (mg/dl) and for fasting glucose level. The analysis was performed by Micro Labe 300 and kits were used of Merck. Other biochemical parameters (Liver function test, Urea,

Complete blood counting, uric acid, electrolytes and protein profile) were used for safety purpose. All the parameters were studied at initial phase for test and control and after completion of trial such as eight weeks (8 weeks), parameters were studied again for test and control. Initial characteristics of patients were determined such as age, body weight, BMI for both test and control patients. Like, the biochemical parameters of the patients, primary blood pressure such as Systolic BP - 24 hours (mmHg) and Diastolic BP - 24 hours (mmHg) was analyzed by manual method for both test and control patients. After eight weeks (8 weeks) trial, blood pressure was determined by same manual method for test and placebo control patients.

## RESULTS

Initial result systolic blood for test patient was  $149.9 \pm 11.2$  mmHg and for placebo control was  $149.2 \pm 10.5$  mmHg. After eight week trial of optimized Captopril 60mg (F-9), systolic blood was reduced ( $140.1 \pm 11.4$  mmHg) as compared to placebo control such as ( $148.9 \pm 11.3$  mmHg). Like systolic blood pressure, initial diastolic blood pressure for test patient was ( $97.7 \pm 7.2$  mmHg) and for placebo was ( $95.3 \pm 7.7$  mmHg) but after eight week trial of optimized Captopril 60mg (F-9), diastolic blood pressure was reduced in test patients ( $86.6 \pm 5.4$  mmHg) as compared to placebo control such as ( $93.9 \pm 7.9$  mmHg). All the Biochemical parameters were not changed for test patient after eight week trial such as (Total Cholesterol  $198.2 \pm 42.3$  (mg/dl), HDL-Cholesterol  $53.8 \pm 13.2$  (mg/dl), LDL-Cholesterol  $113.6 \pm 32.9$  (mg/dl), Triglycerides  $137.8 \pm 88.6$  (mg/dl) and for fasting glucose  $97.4 \pm 11.3$  (mg/dl level) as compare to placebo such as (Total Cholesterol  $192.3 \pm 33.5$  (mg/dl), HDL-Cholesterol  $46.6 \pm 11.3$  (mg/dl), LDL-Cholesterol  $118.4 \pm 25.6$  (mg/dl), Triglycerides  $145.7 \pm 88.6$  (mg/dl) and for fasting glucose  $96.8 \pm 8.8$  (mg/dl) level. The optimized product Captopril 60mg (F-9) showed no biochemical effects regarding lipid metabolism and glucose metabolism. It is due to low dose drug and also no effect of excipient of formulation of F-9.

**Table No.1: Baseline characteristics**

	Captopril 60mg (F-9) (n=60)	Placebo (n=20)
Age (years)	$50.2 \pm 9.5$	$51.1 \pm 9.6$
Male / Female (%)	45.4 / 54.6	37.0 / 63.0
Body weight (Kg)	$69.9 \pm 13.5$	$70.2 \pm 12.2$
BMI (kg/m <sup>2</sup> )	$27.4 \pm 3.6$	$27.8 \pm 3.4$
SBP sitting (mmHg)	$149.9 \pm 11.2$	$149.2 \pm 10.5$
DBP sitting (mmHg)	$97.7 \pm 7.2$	$95.3 \pm 7.7$

**Table No.2: Ambulatory blood pressure monitoring. Mean values of blood pressure**

	Captopril 60mg (F-9) (n=60)	Placebo (n=20)	P-value
Systolic BP - 24 hours (mmHg)			
Baseline	149.9 ± 11.2	149.2±10.5	NS
Week 8	140.1 ± 11.4	148.9±11.3	0.0037
Diastolic BP - 24 hours (mmHg)			
Baseline	97.7 ± 7.2	95.3± 7.7	NS
Week 8	86.6 ± 5.4	93.9± 7.9	0.0001

NS: Non significant, p: probability

**Table No.3: Baseline Biochemical characteristics**

	Captopril 60mg (F-9)(n=60)	Placebo (n=20)
Fasting Blood Glucose(mg/dl)		
Baseline	96.3 ± 11.2	97.3 ± 9.3
Week 8	97.4 ± 11.3	96.8 ± 8.8
Total Cholesterol (mg/dl)		
Baseline	196.8 ± 42.4	193.8 ± 34.3
Week 8	198.2 ± 42.3	192.3 ± 33.5
LDL - Cholesterol (mg\dl)		
Baseline	113.5 ± 32.8	117.8± 23.7
Week 8	113.6 ± 32.9	118.4 + 25.6
HDL - Cholesterol (mg\dl)		
Baseline	52.9 ± 12.8	46.8 ± 11.4
Week 8	53.8 ± 13.2	46.6 ± 11.3
Triglycerides (mg\dl)		
Baseline	137.2 ± 89.3	144.3 ± 88.7
Week 8	137.8 ± 88.6	145.7 ± 88.6

## DISCUSSION

For stroke, hypertension is a major risk factor. Brain tissue loss as a consequence of stroke has been associated with cognitive impairment, in relation to other stroke-specific factors; these strokes may be isolated or strategically located ones (e.g. in the thalamus, angular gyrus, frontal white matter).<sup>26</sup> Also, because hypertension is no single factor but exist with other metabolic risks factors, such as (inflammation of brain, abnormal insulin signaling in the brain) and existing other metabolic syndrome and underlie (cognitive impairment or dementia) in persons with hypertension.<sup>27,28</sup> Patients were selected from different area of orange town and surrounding area, such as Pirabad, Mangopir, Pathan colony, Impear colony, Mastanchali, Metrovell and site area. Total eighty (80) patients were analyzed for Total Cholesterol (mg/dl), HDL-Cholesterol (mg/dl), LDL-Cholesterol (mg/dl), Triglycerides (mg\dl) and for fasting glucose level. The analysis was performed by Micro Labe 300 and kits were used of Merck. Other biochemical parameters (Liver function test, Urea, Complete blood counting, uric acid, electrolytes and protein profile) were used for safety purpose. All the parameters were

studied at initial phase for test and control and after completion of trial such as eight weeks (8 weeks), parameters were studied again for test and control. Initial characteristics of patients were determined such as age, body weight, BMI for both test and control patients. Like, the biochemical parameters of the patients, primary blood pressure such as Systolic BP - 24 hours (mmHg) and Diastolic BP - 24 hours (mmHg) was analyzed by manual method for both test and control patients. After eight weeks (8weeks) trial, blood pressure was determined by same manual method for test and placebo control patients.

The baseline characteristics are shown in Table no1. We can observe that the groups were not different in relation to (age, body mass index, weight, heart rate, systolic and diastolic pressure values). Initial result systolic blood for test patient was  $149.9 \pm 11.2$  mmHg and for placebo control was  $149.2 \pm 10.5$  mmHg. After eight week trial of optimized Captopril 60mg (F-9), systolic blood was reduced ( $140.1 \pm 11.4$  mmHg) as compared to placebo control such as ( $148.9 \pm 11.3$  mmHg). Like systolic blood pressure, initial diastolic blood pressure for test patient was ( $97.7 \pm 7.2$  mmHg) and for placebo was ( $95.3 \pm 7.7$  mmHg) but after eight week trial of optimized Captopril 60mg (F-9), diastolic blood pressure was reduced in test patients ( $86.6 \pm 5.4$  mmHg) as compared to placebo control such as ( $93.9 \pm 7.9$  mmHg). All the Biochemical parameters were not changed for test patient after eight week trial such as (Total Cholesterol  $198.2 \pm 42.3$  (mg/dl), HDL-Cholesterol  $53.8 \pm 13.2$  mg/dl), LDL-Cholesterol  $113.6 \pm 32.9$  mg/dl), Triglycerides  $137.8 \pm 88.6$  (mg\dl) and for fasting glucose  $97.4 \pm 11.3$  mg/dl level) as compare to placebo such as (Total Cholesterol  $192.3 \pm 33.5$  (mg/dl), HDL-Cholesterol  $46.6 \pm 11.3$  mg/dl), LDL-Cholesterol  $118.4 \pm 25.6$  mg/dl), Triglycerides  $145.7 \pm 88.6$  (mg\dl) and for fasting glucose  $96.8 \pm 8.8$  (mg\dl) level. Table No.2 result showed that the optimized product Captopril 60mg (F-9) has best antihypertensive efficacy for long time. For the achieving the goals (pressure levels equal to or lower than 90 mmHg), the treatment of hypertension with optimized product of Captopril 10mg (F-9), we got result more than 68.9% of the patients treated with optimized product. Result showed that optimized product of Captopril 10mg (F-9) didnot affect sympathetic activity and not cause any significant variations of heart rate. Our results showed that the optimized product of Captopril 10mg (F-9) at low doses has a very good biochemical profile with no adverse effects.

The good biochemical profile of the optimized Captopril 10mg (F-9) was found in the study because we use very low dose of drug and the excipients in formulation do not affect the biochemical profile. Diuretics and beta-blockers, promote significantly change lipid profile, glucose metabolism. But in our study, the optimized product Captopril 10mg (F-9) did not alter parameters

of either glucose metabolism or plasma lipids, thus having a neutral biochemical profile even when used for 8 weeks. Table.No.3

The optimized product Captopril 10mg (F-9) is safe because result showed and best for the treatment of hypertension in patients with (metabolic syndrome, diabetes mellitus and dyslipidemias).

## CONCLUSION

The optimized Captopril 60mg (F-9) is an excellent option for the treatment of hypertension with high antihypertensive efficacy, good tolerability and no biochemical effects. It is due to low dose drug and also no effect of excipient of formulation of F-9.

**Conflict of Interest:** The study has no conflict of interest to declare by any author.

## REFERENCES

1. Sykowsky PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular Trends in Long Term Sustained Hypertension, Long Term Treatment and Cardiovascular Morbidity. The Framingham Heart Study 1950-1990. *Circulation* 1996;93: 697-703.
2. MacMahon S, Peto R, Cutler J, et al. Blood Pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. *Lancet* 1990; 335: 765-77.
3. IV Diretrizes Brasileiras de Hipertensão Arterial - Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Cardiologia e Sociedade Brasileira de Nefrologia. *Hipertensão* 2003; 5(4): 126-63.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure JNC 7. *Hypertension* 2003;42: 1206-52.
5. European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension. *J Hypertens* 2003;21: 1011-53.
6. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, et al on behalf of HOT Study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet* 1998;351:1755-62.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;329: 1456-62.
8. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. *BMJ* 1988;297: 1092-95.
9. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. *BMJ* 1991; 303:81-87.
10. Passa P, Leblanc H, Marre M. Effects of enalapril in insulin dependent diabetic subjects with mild to moderate uncomplicated hypertension. *Diabetes Care* 1987; 10: 200-04.
11. Pedersen MM, Schmitz A, Pedersen EB, Danielsen H, Christiansen JS. Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. *Diabet Med* 1988;5: 562-69.
12. Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin converting enzyme in man. *Lancet* 1977;18015:775-778.
13. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. *Clin Pharmacol Ther* 1982;314:452-458.
14. Anaizi NH, Swenson C. Instability of aqueous captopril solutions. *Am J Health Syst Pharm* 1993; 50:486-488.
15. Singh J, Robinson DH. Controlled release kinetics of captopril from tableted microcapsules. *Drug Dev Ind Pharm* 1988;144:545.
16. Wilding IR, Davis SS, Bakhshae M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation. *Pharm Res* 1992; 9:654-657.
17. Sheth PR, Tossounian JL. The hydrodynamic balanced system (HBS): A novel drug delivery system for oral use. *Drug Dev Ind Pharm* 1984; 10:313-339.
18. Chien YW. Potential developments and new approaches in oral controlled-release drug delivery systems. *Drug Dev Ind Pharm* 1983;9:1291-1330.
19. Hoch M, Netz H. Heart failure in pediatric patients. *Thorac Cardiovasc Surg* 2005;53:S129-134.
20. Shaddy RE. Optimizing treatment for chronic congestive heart failure in children. *Crit Care Med* 2001;29:S237-40.
21. Reiffel JA. Formulation substitution: a frequently overlooked variable in cardiovascular drug management. *Prog Cardiovasc Dis* 2004;47:3-10.
22. Bernard RC, Carl JP, John OP, Jaroslav SI, Galina C, Jerzy K, Whedy W, Sandra LS, Andrew AW. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. *JAMA* 2004;291:309-316.
23. Khalida B, Najaf AG, Naheed A. Comparative studies of cimetidine derivative "temalastine" for potential energy calculation by Kitaigorodskii and

- lennard-jones functions. Pak J Biochem Mol Biol 2010; 43: 81-86.
24. Afshan N, Naheed A, Khalida B, Najaf AG, Farhat B. Conformational analysis geometry optimization of nucleosidic antitumor antibiotic showdomycin by Arguslab 4 software. Pak J Pharmacol 2009; 22:78-82.
25. Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(2):103-112.
26. Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke. 1997; 28: 459-463
27. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann NY Acad Sci 2010; 1207: 155-162
28. Gorelick PB. William Feinberg Lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 2005; 36: 875-879.